Those with TP53-mutated disease may benefit from continuous BTK inhibitor therapy, although limited-duration therapy is worthy of discussion.
Talha Munir, MBChB, PhD
Advertisement
Articles by Talha Munir, MBChB, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
3 Things You Should Know About Using Selective Estrogen Receptor Degraders in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2
How Do You Choose The Right Frontline Therapy in CLL Care?
3
From Conference to Practice: Top 5 Takeaways From EHA 2026
4
55 Intramammary Spindle-Cell Lesions: Imaging–Pathology Correlation
5